Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 260 of 5804
-
New catheter aims to suck out stroke clots fast
Disease control Not yet recruitingProspective, single-arm, multi-center study to confirm the performance and safety of the iNstroke 6F and 4F thromboaspiration catheter for the treatment of acute ischemic stroke
Phase: NA • Sponsor: iVascular S.L.U. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for breast cancer patients: extra targeted drug may clear remaining tumors
Disease control Not yet recruitingThis is a prospective, multi-center, single-arm, phase 2 exploratory study to evaluate the efficacy and safety of adding 4 cycles of Trastuzumab Rezetecan (T-DXh), an anti-HER2 antibody-drug conjugate, as continued neoadjuvant therapy in patients with early or locally advanced HE…
Phase: PHASE4 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for myeloma: phase 3 trial pits JNJ-79635322 against current drug
Disease control Recruiting nowThe purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for rare blood disorder: experimental drug TGD001 enters human trials
Disease control Not yet recruitingThis is a Phase 1/2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or clinical diagnosis of an acute Thrombotic Microangiopathy …
Phase: PHASE1, PHASE2 • Sponsor: TargED Biopharmaceuticals B.V. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Two probes better than one? new study aims to cut cervical cancer in women with HIV
Prevention Not yet recruitingCervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the Wor…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 12:25 UTC
-
New drug duo aims to fight kidney cancer without losing the kidney
Disease control Not yet recruitingThis is a prospective, multicentre, single-arm phase II study evaluating a response-adapted kidney-preserving strategy in patients with HER2-positive high-risk upper tract urothelial carcinoma (UTUC). Patients will receive neoadjuvant disitamab vedotin plus tislelizumab, followed…
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New vaccine takes on deadly brain tumors in early trial
⭐️ VACCINE ⭐️ ENROLLING_BY_INVITATIONThis study is designed to treat patients who have been diagnosed with brain cancer, including glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). The treatment uses immunomodulatory vaccine generated by autologous dendritic cells (DCs) pulsed with genetically modified…
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:02 UTC
-
Triple therapy aims to wipe out rectal cancer before surgery
Disease control Not yet recruitingThe goal of this clinical trial is conducted to evaluate the neoadjuvant regimen of short-course radiotherapy (SCRT) followed by NALIRIFOX chemotherapy plus Pucotenlimab immunotherapy for high-risk locally advanced rectal cancer. The main questions it aims to answer are: 1. Doe…
Phase: PHASE2 • Sponsor: Wang Xin • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at brain tumors
Disease control Not yet recruitingQH101 is an allogeneic TCR-enhanced Vδ2 T cell therapy product engineered to express BTN protein-specific binding elements on the cell surface. This innovative approach harnesses the natural cytotoxic capabilities of Vδ2 T cells while augmenting their ability to recognize BTN pro…
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a breath test replace finger pricks for diabetes?
Diagnosis Recruiting nowThe purpose of this study is to determine whether an array of biosensors can noninvasively identify hyperglycemic or hypoglycemic events in persons diagnosed with diabetes through noninvasive detection of volatile organic compounds (VOCs) in exhaled breath.
Phase: NA • Sponsor: Indiana University • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
New hope for kids with tough cancers: targeted drug trial launches
Disease control Recruiting nowThere is a significant unmet medical need for effective therapies for pediatric relapsed/refractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug Vedotin demonstrated a manageable safety profile a…
Phase: PHASE1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a cheap arthritis drug cut stroke survivors' heart risks?
Disease control Not yet recruitingData indicate that patients with intracerebral hemorrhage (ICH) are at high risk for thromboembolic events and disability that is not being sufficiently mitigated by current treatment strategies. This is aggravated by the cessation of antithrombotic medications for significant pe…
Phase: PHASE3 • Sponsor: Population Health Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Can a nasal spray of stem cell 'Messages' slow Alzheimer's?
Disease control Recruiting nowThis study is divided into two phases: a dose-escalation phase and an expansion cohort phase. The dose-escalation phase is a single-center study, while the expansion cohort phase is a multicenter, prospective, randomized, double-blind, placebo-controlled study.
Phase: PHASE1, PHASE2 • Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug could keep lymphoma at bay in hepatitis b patients
Disease control Recruiting nowTo evaluate the efficacy and safety of chidamide monotherapy as maintenance treatment in patients with diffuse large B-cell lymphoma (DLBCL) and HBV infection following initial response to R-CHOP therapy, and to provide evidence for the clinical application of chidamide.
Phase: PHASE3 • Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for HER2+ breast cancer: experimental drug JSKN003 faces off against standard therapy
Disease control Not yet recruitingThis study is a randomized, controlled, open-label, multicenter, phase II superiority clinical trial. The planned study population consists of participants with HER2-positive recurrent or metastatic breast cancer who have not previously received systemic therapy for advanced dise…
Phase: PHASE2 • Sponsor: Shanghai JMT-Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a pill under the tongue prevent dangerous bleeding after birth?
Prevention Not yet recruitingAn open-label, randomized, single-center, dose ascending trial will be conducted to evaluate the efficacy and safety of sublingual oxytocin for the prevention of post-partum hemorrhage caused by uterine atony in term pregnant women having an uncomplicated vaginal delivery.
Phase: PHASE2 • Sponsor: Insud Pharma • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
New pill aims to slow Parkinson's progression in Early-Stage patients
Disease control Not yet recruitingThe purpose of this study is to assess the efficacy, the safety, and the effect on biomarkers of 2 dose levels of oral GT-02287 over placebo after 48 weeks of treatment in treated and untreated participants with early PD.
Phase: PHASE2 • Sponsor: Gain Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Robot arm vs expert hand: can tech beat tremor in prostate biopsies for obese men?
Diagnosis Not yet recruitingThe trial aims to find out if using a robotic system to help perform prostate biopsies is better than having a highly experienced doctor perform the biopsy by hand in men with a high Body Mass Index (BMI). While MRI-guided prostate biopsies are highly effective, carrying them ou…
Phase: NA • Sponsor: Shanghai East Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New hope for relapsed blood cancer: Three-Drug combo enters trials
Disease control Not yet recruitingThis is a phase 1b/2a, open-label trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of lisaftoclax in combination with chidamide and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo shows promise in shrinking esophageal tumors before surgery
Disease control Not yet recruitingThis is a prospective, single-arm, exploratory clinical study designed to evaluate the efficacy and safety of retlirafusp alfa combined with chemotherapy (nab-paclitaxel and cisplatin) as a neoadjuvant therapy for patients with resectable locally advanced thoracic esophageal squa…
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC